OncLive TV

Adanma Ayanambakkam, MD, MS, discusses the background of the phase 1a FIT-001 trial of darlifarnib plus cabozantinib in RCC.

Meredith Pelster, MD, MSCI, discusses phase 2a data for atebimetinib plus chemotherapy and the design of a phase 2 trial in pancreatic cancer.

Zev A. Wainberg, MD, discusses early-phase INCB161734 data in refractory pancreatic cancer and the evolving RAS inhibitor landscape.

Paul E. Oberstein, MD, discusses a personalized mRNA vaccine being evaluated in pancreatic ductal adenocarcinoma and why it matters.

Daniel Morillo, MD, discusses AEs associated with golcadomide plus rituximab in relapsed/refractory follicular lymphoma.

Daniel Morillo, MD, discusses efficacy data for golcadomide plus rituximab in relapsed/refractory follicular lymphoma.

Javier Cortés, MD, PhD, discusses the design of the ASPEN-09-03 trial and the development of CD47 as a biomarker in pretreated HER2-positive breast cancer.

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses first-line efficacy data for divarasib plus pembrolizumab in KRAS G12C+ NSCLC from the KRASCENDO-170 study.

Madhur K. Garg, MD, MBA, MBBS, discusses the safety of proton therapy in patients with head and neck cancer.

Sara A. Hurvitz, MD, FACP, discusses the SERENA-6 data and the case for an early ctDNA-guided switch to camizestrant in HR-positive breast cancer.

Daniel Morillo, MD, discusses the mechanism of action of golcadomide as a potential treatment for relapsed/refractory follicular lymphoma.

Alexandra Leary, MD, PhD, discusses PFS and safety data from the phase 2 TEDOVA trial of Tedopi plus pembrolizumab in platinum-sensitive ovarian cancer.

Alessandro A. Viansone, MD, discusses the SATEEN study, ADC-after-ADC sequencing, and maintaining HER2 selective pressure in metastatic breast cancer.

Alessandro A. Viansone, MD, discusses balancing ADCs such as T-DXd against low-toxicity chemotherapy in HER2-positive breast cancer therapy de-escalation.

Michael J. Morris, MD, discusses key ongoing clinical trials in prostate cancer.

Alessandro A. Viansone, MD, discusses data that support chemotherapy de-escalation in HER2-positive breast cancer.

Shailender Bhatia, MD, discusses phase 3 ADAM trial data on relapse-free survival and safety with adjuvant avelumab in Merkel cell carcinoma.

Matteo S. Carlino, MBBS, PhD, FRACP, discusses how neoantigen-specific T cells link to intismeran autogene’s KEYNOTE-942 recurrence benefit.

Estelamari Rodriguez, MD, MPH, discusses the rationale for combining LAG-3 and PD-1 blockade to overcome immunotherapy resistance in NSCLC.

Rahul Banerjee, MD, FACP, discusses the FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in relapsed/refractory myeloma.

Madhur K. Garg, MD, MBA, MBBS, discusses findings from a phase 3 study of proton therapy in patients with head and neck cancer.

Michael J. Morris, MD, discusses updated data from the phase 3 PSMAddition trial supporting lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA-positive mHSPC.

Toon Van Gorp, discusses PFS data with TUB-040 in platinum-resistant ovarian cancer.

Madhur K. Garg, MD, MBA, MBBS, discusses the use of proton therapy in head and neck cancer.

Javier Cortés, MD, PhD, discusses additional TROPION-Breast02 end points supporting the first-line use of Dato-DXd in metastatic TNBC.

Michael J. Morris, MD, discusses phase 3 PSMAddition trial data supporting lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA-positive mHSPC.

Rafael Fonseca, MD, discusses why CAR T-cell therapy could be considered at first relapse in multiple myeloma.

William Phillips, MD, discusses real-world findings on RET inhibitor dose reductions and clinical outcomes in advanced RET fusion–positive NSCLC.

Jordyn Silverstein, MD, MSc, discusses updated data with abemaciclib plus hormonal therapy in ER-positive endometrial cancer and low-grade serous ovarian cancer.

Adam D. Cohen, MD, discusses the mechanism of action of cevostamab in relapsed/refractory multiple myeloma.